Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.83 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.83 |
| ▸ | ERBB3 | P21860 | 2/20 | 0.83 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.83 |
| ▸ | BTK | Q06187 | 3/20 | 0.64 |
| ▸ | ITK | Q08881 | 3/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16407979 | 0.91 | EGFR (1.00) | EGFRERBB2ERBB3ERBB4BTK | |
| SCHEMBL19360697 | 0.89 | EGFR (0.74) | EGFRERBB2ERBB3ERBB4BTK | |
| SCHEMBL4560138 | 0.89 | EGFR (1.00) | EGFRERBB2ERBB3ERBB4BTK | |
| SCHEMBL9923758 | 0.88 | EGFR (0.82) | EGFRERBB2ERBB3ERBB4BTK | |
| SCHEMBL9923759 | 0.87 | EGFR (0.81) | EGFRBTKITK | |
| SCHEMBL9923762 | 0.84 | EGFR (0.82) | EGFRBTKITK | |
| SCHEMBL19360704 | 0.83 | EGFR (0.72) | EGFRBTKITK | |
| SCHEMBL10059499 | 0.83 | EGFR (0.81) | EGFRERBB2ERBB3ERBB4BTK | |
| SCHEMBL9923763 | 0.83 | EGFR (0.82) | EGFRBTKITK | |
| SCHEMBL18371447 | 0.81 | JAK3 (0.81) | EGFRERBB3ERBB4BTKITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157426-A1 | MUTANT-SELECTIVE EGFR INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157426-A1 | MUTANT-SELECTIVE EGFR INHIBITORS AND USES THEREOF | EGFR, ERBB3, ERBB2 | EGFR 1/4885ERBB2 3/4885ERBB3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.